• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Synthorx Announces Closing of Initial Public Offering

    Gabrielle Lakusta
    Dec. 13, 2018 09:20AM PST
    Biotech Investing

    Synthorx (Nasdaq:THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its previously announced initial public offering of 13,699,636 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,786,909 additional …

    Synthorx (Nasdaq:THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its previously announced initial public offering of 13,699,636 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,786,909 additional shares of common stock, at a public offering price of $11.00 per share.

    As quoted in the press release:

    The aggregate gross proceeds to Synthorx from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $150.7 million. All of the shares in the offering were offered by Synthorx. The shares commenced trading on the Nasdaq Global Select Market on December 7, 2018 under the ticker symbol “THOR.”

    Jefferies LLC, Leerink Partners LLC and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as lead manager for the offering.

    Click here to read the full press release.

    nasdaq:thor
    The Conversation (0)

    Go Deeper

    AI Powered
    Life Science Outlook

    Life Science Outlook

    Syntheia Announces Closing of the Final Tranche of Private Placement

    Syntheia Announces Closing of the Final Tranche of Private Placement

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES